Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity

Clinical Pharmacology and Therapeutics

Volumn 67, Issue 5, 2000, Pages 466-477

  Hamelin, Bettina A ^a   Bouayad, Asmàa ^b   Méthot, Julie ^b   Jobin, Jean ^b   Desgagnés, Pierre ^b   Poirier, Paul ^b   Allaire, Joakim ^b   Dumesnil, Jean ^b   Turgeon, Jacques ^b  

^a Shire Canada   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIPHENHYDRAMINE; METOPROLOL;

ADULT; ARTICLE; BIOTRANSFORMATION; CHRONOTROPISM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG METABOLISM; DRUG SAFETY; HUMAN; HYPERTENSION; INOTROPISM; ISCHEMIC HEART DISEASE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0034074170     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.106464     Document Type: Article

References (51)

1. 1-receptor-antagonist drugs. N Engl J Med 1994;330:1663-9.
2. 1-receptor antagonist drugs. J Allergy Clin Immunol 1996;98:S307-S318.
3. 1-receptor antagonists: worth the price? Ann Allergy 1992;69:163-5.
4. 4. Woosley RL, Chen Y, Freiman JP, Gillis RA. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993;269:1532-6.
5. 5. Pinney SP, Koller BS, Franz MR, Woosley RL. Terfenadine increases the QT interval in isolated guinea pig heart. J Cardiovasc Pharmacol 1995;25:30-4.
6. 1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. Circ Res 1995;76:110-9.
7. 7. Food and Drug Administration. Terfenadine: proposal to withdraw approval of two new drug applications and one abbreviated new drug application. Opportunity for a hearing. 1-17.13-1-1997. Washington (DC): Docket No. 96N-0512.
8. 1 antagonist promethazine in human liver microsomes. Pharmacogenetics 1996;6:449-57.
9. 9. Salcedo JA, Yasuda SU, Murphy MP, Woosley RL, Flockhart DA. Stereoselective inhibition of CYP2D6 by chlorpheniramine [abstract]. Clin Pharmacol Ther 1995;57:149.
10. 1 receptor antagonists. Drug Metab Dispos 1998;26:536-9.
11. 11. Khalifa M, Drolet B, Daleau P, Lefez C, Gilbert M, Plante S, et al. Block of potassium currents in guinea pig ventricular myocytes and lengthening of cardiac repolarization in man by the histamine H1 receptor antagonist diphenhydramine. J Pharmacol Exp Ther 1999;288:858-65.
12. 12. Turgeon J, Pavlou HN, Wong W, Funck-Brentano C, Roden DM. Genetically determined steady-state interaction between encainide and quinidine in patients with arrhythmias. J Pharmacol Exp Ther 1990;255:642-9.
13. 13. Turgeon J, Fiset C, Giguère R, Gilbert M, Moerike K, Rouleau JR, et al. Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man. J Pharmacol Exp Ther 1991;259:789-98.
14. 14. Lennard MS, Tucker GT, Silas JH, Woods HF. Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol. Xenobiotica 1986;16:435-47.
15. 15. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/sparteine metabolism: clinical aspects. Pharmacol Ther 1990;46:377-94.
16. 16. Hamelin BA, Turgeon J, Vallée F, Bélanger PM, Paquet F, LeBel M. The disposition of fluoxetine but not of sertraline is altered in poor metabolizers of debrisoquine. Clin Pharmacol Ther 1996;60:512-21.
17. 17. Brøsen K, Sindrup SH, Skjelbo E, Nielsen KK, Gram LF. Role of genetic polymorphism in psychopharmacology: an update. Psychopharmacol Ser 1993;10:199-211.
18. 18. Hjalmarson A, Herlitz J, Malek I, Ryden L, Vedin A, Waldenstrom A, et al. Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomised trial. Lancet 1981;2:823-7.
19. 19. Soriano JB, Hoes AW, Meems L, Grobbee DE. Increased survival with β-blockers: importance of ancillary properties. Prog Cardiovasc Dis 1997;39:445-56.
20. 20. MaGourty JC, Silas JH, Lennard MS, Tucker GT, Woods HF. Metoprolol metabolism and debrisoquine polymorphism: population and family studies. Br J Clin Pharmacol 1995;20:555-6.
21. 21. Lennard MS, Tucker GT, Woods HF, Silas JH, Iyun AO. Stereoselective metabolism of metoprolol in Caucasians and Nigerians: relationship to debrisoquine oxidation phenotype. Br J Clin Pharmacol 1989;27:613-6.
22. 22. Lennard MS, Silas JH, Freestone S, Ramsay LE, Tucker GT, Woods HF. Oxidation phenotype: a major determinant of metoprolol metabolism and response. N Engl J Med 1982;307:1558-60.
23. 23. Clifton GD, Harrison MR, DeMaria AN. Influence of beta-adrenergic blockade upon hemodynamic response to exercise assessed by Doppler echocardiography. Am Heart J 1990;120:579-85.
24. 24. Clifton GD, Chandler MHH, Pennell AT, McCoy RA, Harrison MR. Differential response of β-adrenergic receptor-mediated heart rate and aortic blood flow acceleration to timolol. Clin Pharmacol Ther 1992;51:296-301.
25. 25. Lennard MS, Silas JH, Smith AJ, Tucker GT. Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection. J Chromatogr 1977; 133:161-6.
26. 26. Hildebrand M, Seifert W, Reichenberger A. Determination of dextromethorphan metabolizer phenotype in healthy volunteers. Eur J Clin Pharmacol 1989;36:315-8.
27. 1795 in exon 3 generates a premature stop codon. Pharmacogenetics 1994;4:271-4.
28. 28. Daly AK, Steward A. Use of the expand long template PCR system in genotyping for polymorphisms in the human cytochrome P450 CYP2D6 gene. Biochemica 1995;4:31-2.
29. 29. Steen VM, Andreassen OA, Daly AK, Tefre T, Borresen AL, Idle JR, et al. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 1995;5:215-23.
30. 30. Evert B, Griese EU, Eichelbaum M. A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine. Naunyn Schmiedebergs Arch Pharmacol 1994;350:434-9.
31. 31. Heim MH, Meyer UA. Genetic polymorphism of debrisoquine oxidation: restriction fragment analysis and allele-specific amplification of mutant alleles of CYP2D6. Methods Enzymol 1991;206:173-83.
32. 32. Albert KS, Hallmark MR, Sakmar E, Weidler DJ, Wagner JG. Pharmacokinetics of diphenhydramine in man. J Pharmacokinet Biopharm 1975;3:159-70.
33. 33. Lennard MS. Quantitative analysis of metoprolol and three of its metabolites in urine and liver microsomes by high-performance liquid chromatography. J Chromatogr 1985;342:199-205.
34. 34. Sebaldt RJ, Kreeft JH. Efficient pharmacokinetic modeling of complex clinical dosing regimens: the universal elementary dosing regimen and computer algorithm EDFAST. J Pharm Sci 1987;76:93-100.
35. 35. Harrison MR, Clifton GD, DeMaria AN. Hemodynamic effects of calcium channel and β-receptor antagonists: evaluation by Doppler echocardiography. Am Heart J 1991;121:126-33.
36. 1-receptor antagonists: clinical pharmacology and therapeutics. J Allergy Clin Immunol 1989;84: 845-61.
37. 37. Chiou WL, Athanikar NK, Huang SM. Long half-life of chlorpheniramine. N Engl J Med 1979;300:501.
38. 38. Huang SM, Athanikar NK, Sridhar K, Huang YC, Chiou WL. Pharmacokinetics of chlorpheniramine after intravenous and oral administration in normal adults. Eur J Clin Invest 1982;22:359-65.
39. 39. Carruthers SG, Shoeman DW, Hignite CE, Azarnoff DL. Correlation between plasma diphenhydramine level and sedative and antihistamine effects. Clin Pharmacol Ther 1978;23:375-82.
40. 40. Spector R, Choudhury AK, Chiang CK, Goldberg MJ, Ghoneim MM. Diphenhydramine in Orientals and Caucasians. Clin Pharmacol Ther 1980;28:229-34.
41. 41. Lennard MS, Tucker GT, Silas GH, Freestone S, Ramsay LE, Woods HF. Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquine metabolizers. Clin Pharmacol Ther 1983;34:732-7.
42. 42. Alvan G. Clinical consequences of polymorphic drug oxidation. Fundam Clin Pharmacol 1991;5:209-28.
43. 43. de Groot MJ, Vermeulen NPE, Kramer JD, van Acker FAA, Donné-Op den Kelder GM. A three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structures of P450 101, P450 102, and P450 108. Chem Res Toxicol 1996;9:1079-91.
44. 44. de Groot MJ, Bijloo GJ, Martens BJ, van Acker FAA, Vermeulen NPE. A refined substrate model for human cytochrome P450 2D6. Chem Res Toxicol 1997;10:41-8.
45. 45. Rekka E, Timmermann H, Bast A. Structural features of some diphenhydramine analogues that determine the interaction with rat liver cytochrome P-450. Agents Actions 1989;27:184-7.
46. 46. Glassman JN, Dugas JE, Tsuang MT, Loyd DW. Idiosyncratic pharmacokinetics complicating treatment of major depression in an elderly woman. J Nerv Ment Dis 1985;173:573-6.
47. 47. Zhou HH, Wood AJJ. Stereoselective disposition of carvedilol is determined by CYP2D6. Clin Pharmacol Ther 1995;57:518-24.
48. 48. Daley PJ, Sagar KB, Wann LS. Doppler echocardiographic measurement of flow velocity in the ascending aorta during supine and upright exercise. Br Heart J 1985;54:562-7.
49. 49. Bryg RJ, Labovitz AJ, Mehdirad AA, Williams GA, Chaitman BR. Effect of coronary artery disease on Doppler-derived parameters of aortic flow during upright exercise. Am J Cardiol 1986;58:14-9.
50. 50. McCoy RA, Clifton GD, Clementi WA, Smith MD, Garvey TQ, Wermeling DP, et al. Pharmacodynamics of racemic and S(-)-atenolol in humans. J Clin Pharmacol 1994;34:816-22.
51. 51. Clifton GD, Pennell AT, Harrison MR. Pharmacodynamics of propranolol on left ventricular function: assessment by Doppler echocardiography. Clin Pharmacol Ther 1990;48:431-8.